Drug pricing makes healthcare one of the more politically exposed sectors, so a likely Democratic House might look like a headwind for biotech. For early-stage company creation in particular, the picture is more favorable than it appears, for four reasons.
Venture biotech runs on a longer clock than Washington.
A biotech company founded today will typically reach its key value milestones years from now, after the 2028 election and quite possibly after the next one too. What matters most over that horizon is demand from large pharma for new drugs, and that demand is structural. Over $230B of biopharma revenue will lose exclusivity by 2030, putting up to 65% of some big pharma companies’ current sales at risk. Buyers are reaching earlier to fill the gap: in H1 2026, 63% of deals targeted pre-Phase III assets, up from 39% across 2025 and a record for early and mid-stage acquisitions. A patent cliff doesn’t change with control of Congress.1,2
A patent cliff doesn’t change with control of Congress.
Divided government makes sweeping pricing legislation harder to pass.
Pricing pressure won’t disappear, but how it’s applied matters. RSM notes that congressional control will shape whether federal drug pricing policy is codified and expanded, or continues mainly through agency action and oversight. Expanding Medicare negotiation by statute would require both chambers and a presidential signature. With control split, the more likely result is incremental policy, which is easier for long-horizon investors to underwrite than a sudden rewrite.3
A Democratic House strengthens Congress’s hand on research funding.
Early-stage biotech depends on the academic science behind it. Congress has already shown it will push back on deep cuts: NIH’s FY2026 enacted program level was $46.5 billion, rather than the President’s proposed reduction. A House majority that controls appropriations is well placed to defend that funding, protecting the research base that early-stage investors draw on.4
A must-pass FDA bill forces bipartisan action in 2027.
The drug, device, generic and biosimilar user fee programs all expire on September 30, 2027, so Congress must pass legislation for the FDA to keep collecting fees from industry. That deadline compels the two parties to agree on FDA funding and review processes regardless of who controls each chamber. There is also common ground to build on: onshoring of manufacturing and clinical trials has strong bipartisan momentum, and the user fee reauthorization could be its legislative vehicle.5,6
The counterarguments investors should weigh
A Democratic Congress would push to expand price negotiation. Analysts expect that Democrats would likely pursue expansion of the Medicare Drug Price Negotiation Program, along with broader out-of-pocket caps and further PBM reforms. Critics argue that pricing pressure of this kind reduces the expected return on new drugs and so has a chilling effect on the development of new medicines. Lower expected drug revenues ultimately feed through to what acquirers will pay for early-stage companies.5,7
Pricing pressure won’t stop with Congress. The administration is likely to keep pressing companies to adopt most-favored-nation pricing, so pricing decisions are increasingly shaped by executive leverage rather than statutory reform. Gridlock in Congress doesn’t remove that.8
Early-stage funding remains tight. Despite strong M&A, venture funding stayed weak for early-stage companies. Some buyers still prefer de-risked assets, and the market has shifted toward bolt-on acquisitions targeting Phase 2 and Phase 3 assets. Early-stage companies may need more capital and more time to reach the point where acquirers engage.9,10
Sources
- 1. IQVIA
- 2. BioXconomy
- 3. RSM US
- 4. Intuition Labs
- 5. Legal 500
- 6. PharmExec
- 7. National Review
- 8. ML Strategies
- 9. Drug Patent Watch
- 10. BioMed Nexus
For information only; not an offer to sell or a solicitation of an offer to buy any security, and not investment advice.
Back to Insights